Orchestra BioMed (OBIO)
Develops partnership-enabled device therapies for hypertension and artery disease.
Something off on this page? Send us feedback.
Develops investigational cardiovascular-device therapies through partnerships with medical-device companies. AVIM Therapy targets hypertension in pacemaker-indicated patients, while Virtue SAB is a sirolimus-delivering balloon candidate for artery disease.
Develops cardiovascular-device therapies through strategic partnerships with medical-device companies. Its lead investigational programs are AVIM Therapy, a pacemaker-compatible bioelectronic therapy for hypertension, and Virtue SAB, a sirolimus-delivering balloon candidate for artery disease.
AVIM is being evaluated in patients who have uncontrolled hypertension and a pacemaker indication. Virtue SAB is being studied for coronary in-stent restenosis, with no balloon coating or permanent implant.
The operating model pairs development of its therapies with partners intended to support global commercialization. Program progress depends on pivotal clinical trials, and the Virtue partnership was reset after the Terumo agreement ended.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | Piper Sandler | Reiterate | Overweight | $10 | ||
| May 13, 2026 | Barclays | Reiterate | Overweight | $12 | $13 | |
| Jan 9, 2026 | Barclays | Reiterate | Overweight | $12 | ||
| Aug 20, 2025 | BTIG | Downgrade | Buy | Neutral |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $110.0M · Total debt $70.8M · Total assets $115.7M · Shareholders' equity $29.4M
- Revenue
- $88.0K
- Operating income
- −$22.4M
- Net income
- −$23.8M
No dividends on record.
| Institutions66 holders · as of Mar 31, 2026 | 38.42% | 23.09M shares | |
| Insiders10 holders · as of Sep 2, 2026 | 6.13% | 3.68M shares | |
| Strategic holders2 holders · as of Feb 27, 2026 | 21.51% | 12.93M shares | |
| Otherremainder | 33.94% | 20.40M shares |
60.11M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Medtronic plc1,2Strategic10 percent owner | 16.77% | 10.08M | 13Gfiled Feb 27, 2026 ↗ |
RTW Investments, LPInstitution | 13.82% | 8.31M | 13Fas of Mar 31, 2026 |
Perceptive Advisors LLCInstitution | 8.38% | 5.04M | 13Fas of Mar 31, 2026 |
Tasso Partners, LLCStrategic | 4.74% | 2.85M | 13Gfiled Nov 19, 2025 ↗ |
Vanguard Capital Management LLCInstitution | 3.67% | 2.20M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Medtronic plc's transaction reports restate only vehicles that traded; the 2026 ownership statement (10.08M) is used instead.
- Medtronic plc reports a block also reported by Perceptive Advisors LLC; it is counted once, under Perceptive Advisors LLC.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Darren Sherman | director, officer: See Remarks | −15,000 | $4.94 |
| Aug 26, 2026 | Darren Sherman | director, officer: See Remarks | +2,000 | $5.33 |
| Aug 3, 2026 | Darren Sherman | director, officer: See Remarks | −15,000 | $4.09 |
| Jul 1, 2026 | Darren Sherman | director, officer: See Remarks | −15,000 | $4.27 |
| Jun 1, 2026 | Darren Sherman | director, officer: See Remarks | −15,000 | $3.87 |
- Boston Scientific
AGENT DCB is the pivotal-trial comparator in coronary ISR.
- Abbott
Cardiac rhythm management competitor in pacemaker-enabled hypertension.
- Medtronic
Interventional cardiology competitor alongside an AVIM collaboration.
- BD
Interventional cardiology competitor in artery-disease devices.
- Philips (ADR)
Interventional cardiology competitor in artery-disease devices.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Orchestra BioMed | $4.95 | +1.02% | $296.4M | — | — | 9.3 | −89.5% |
| Boston Scientific | $48.50 | +0.26% | $71.90B | 19.7 | 14.6 | 3.4 | +7.5% |
| Abbott | $110.50 | +0.04% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| Medtronic | $92.50 | +0.33% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| BD | $189.24 | +0.88% | $51.67B | 56.5 | 14.2 | 2.5 | −9.6% |
| Philips (ADR) | $26.22 | −0.62% | $25.77B | 19.6 | 13.5 | 1.3 | −2.9% |
| Median | 22.7 | 14.6 | 3.1 | +7.5% |